An Open-label Phase I Study of Once Every Three Weeks Intravenous Treatment With BI 6727 in Japanese Patients With Advanced Solid Tumours.
Phase of Trial: Phase I
Latest Information Update: 02 Dec 2015
At a glance
- Drugs Volasertib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 02 Dec 2015 Results published in the Investigational New Drugs
- 25 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 May 2014 Planned End Date changed from 1 Aug 2014 to 1 Jun 2014 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History